Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease
Authors
Keywords
-
Journal
Nature Communications
Volume 4, Issue 1, Pages -
Publisher
Springer Nature
Online
2013-11-05
DOI
10.1038/ncomms3735
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BRCA1 loss activates cathepsin L–mediated degradation of 53BP1 in breast cancer cells
- (2013) David A. Grotsky et al. JOURNAL OF CELL BIOLOGY
- Imaging of Protein Synthesis: In Vitro and In Vivo Evaluation of 44Sc-DOTA-Puromycin
- (2012) Sebastian Eigner et al. MOLECULAR IMAGING AND BIOLOGY
- Protease-Activated Drug Development
- (2012) Ki Young Choi et al. Theranostics
- Quantitative Glycoproteomic Analysis of Optimal Cutting Temperature-Embedded Frozen Tissues Identifying Glycoproteins Associated with Aggressive Prostate Cancer
- (2011) Yuan Tian et al. ANALYTICAL CHEMISTRY
- A new pathway that regulates 53BP1 stability implicates Cathepsin L and vitamin D in DNA repair
- (2011) Ignacio Gonzalez-Suarez et al. EMBO JOURNAL
- Hdac3 Is Essential for the Maintenance of Chromatin Structure and Genome Stability
- (2010) Srividya Bhaskara et al. CANCER CELL
- Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
- (2010) J.- H. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
- (2010) Julia M. Wagner et al. Clinical Epigenetics
- JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
- (2009) J. Arts et al. CLINICAL CANCER RESEARCH
- Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes
- (2009) Angela Nebbioso et al. EMBO REPORTS
- Histone deacetylase inhibitors: Potential in cancer therapy
- (2009) P.A. Marks et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Synthesis, Crystallization, and Biological Evaluation of an Orally Active Prodrug of Gemcitabine
- (2009) David M. Bender et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cathepsin L, target in cancer treatment?
- (2009) Jacqueline M. Lankelma et al. LIFE SCIENCES
- SUnSET, a nonradioactive method to monitor protein synthesis
- (2009) Enrico K Schmidt et al. NATURE METHODS
- Genetic dissection of histone deacetylase requirement in tumor cells
- (2009) M. Haberland et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
- (2008) Nagma Khan et al. BIOCHEMICAL JOURNAL
- HDAC family: What are the cancer relevant targets?
- (2008) Olaf Witt et al. CANCER LETTERS
- Cathepsin L Proteolytically Processes Histone H3 During Mouse Embryonic Stem Cell Differentiation
- (2008) Elizabeth M. Duncan et al. CELL
- Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay
- (2008) C. Bonfils et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started